Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
Journal of Clinical Oncology, 07/01/09
Visvanathan K et al. - In a study to update the 2002 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction, it was determined that in women at increased risk for BC, tamoxifen (20 mg/d for 5 yrs) may be offered to reduce risk of invasive ER-positive BC, with benefits for at least 10 yrs. In postmenopausal women, raloxifene (60 mg/d for 5 yrs) may also be considered. Use of aromatase inhibitors, fenretinide, or other selective estrogen receptor modulators to lower BC risk is not recommended outside of a clinical trial. Discussion of risks and benefits of preventive agents is critical to pt decision making.
Methods- A literature search identified relevant randomized trials published since 2002.
- Primary outcome of interest was BC incidence (invasive and noninvasive).
- Secondary outcomes included BC mortality, adverse events, and net health benefits.
- An expert panel reviewed the literature and developed updated consensus guidelines.
- 17 articles met inclusion criteria.
- In premenopausal women, tamoxifen for 5 yrs reduces risk of BC for at least 10 yrs, particularly estrogen receptor (ER) –positive invasive tumors.
- Women ≤50 yrs of age experience fewer serious side effects.
- Vascular and vasomotor events do not persist post-treatment across all ages.
- In postmenopausal women, raloxifene and tamoxifen reduce the risk of ER-positive invasive BC with equal efficacy.
- Raloxifene is associated with a lower risk of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen in postmenopausal women.
- No evidence exists establishing whether a reduction in BC risk from either agent translates into reduced BC mortality.
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group
Journal of Clinical Oncology, 10/19/09
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Pomegranate fruit extract impairs invasion and motility in human breast cancer
Integrative Cancer Therapies , 10/12/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Nonsteroidal anti-inflammatory drugs
Cancer, 10/16/09
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


